Endoscopy and anesthesia outcomes associated with glucagon-like peptide-1 receptor agonist use in patients undergoing outpatient upper endoscopy

🥉 Top 5% JournalJan 17, 2025Gastrointestinal endoscopy

Effects of diabetes drugs on anesthesia and procedure outcomes in patients having outpatient upper digestive tract exams

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Patients taking GLP-1 receptor agonists (GLP-1RAs) have a 3.80 times higher odds of solid retained gastric contents during upper endoscopy compared to those not taking these medications.

Solid retained gastric contents were significantly more common in the GLP-1RA group during upper endoscopy, as indicated by a multivariate analysis.
The prevalence of diabetes mellitus was higher in the GLP-1RA group (68%) compared to the control group (57%).
Procedures were aborted more frequently in the GLP-1RA group (1.3%) than in the control group (0%).
Rates of hypoxia during procedures were similar between the two groups, with 0.2% in the GLP-1RA group and 0.3% in the control group.
No cases of pulmonary aspiration were reported in either group.

AI simplified

BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) can cause delayed gastric emptying, raising concern for retained gastric contents (RGC) during endoscopy and adverse anesthesia events. The aim of this study was to determine associations between GLP-1RA and endoscopy and anesthesia outcomes.

METHODS: This single-center, retrospective cohort study examined patients prescribed GLP-1RAs who underwent outpatient endoscopy stratified according to exposure at the time of endoscopy. The GLP-1RA group had ≥6 weeks of exposure as confirmed by pharmacy dispensation reports. The control group were patients not taking GLP-1RAs at the time of endoscopy (prescription never filled, discontinued ≥6 weeks prior, or started postendoscopy). The outcomes were the presence of solid RGC, aborted procedures, or any adverse anesthesia events.

RESULTS: A total of 598 patients were included in the study; 360 were taking GLP-1RAs, and 298 were control subjects. Baseline characteristics, including age, sex, chronic opiate use, gastroparesis, and prior gastric surgery, were similar, but diabetes mellitus was more prevalent in the GLP-1RA group (68% vs 57%; P = .005). The odds of solid RGC was significantly higher in the GLP-1RA group in multivariate analysis (odds ratio, 3.80; 95% confidence interval, 1.57-9.21; P = .003), but odds were not increased in patients undergoing concurrent colonoscopy. More patients in the GLP-1RA group had procedures aborted (1.3% vs 0%; P = .021), but rates of hypoxia were similar (.2% vs .3%; P = .341). There were no cases of pulmonary aspiration.

CONCLUSIONS: Patients taking GLP-1RAs have increased rates of solid RGC during upper endoscopy (but not with concurrent colonoscopy) and higher rates of aborted procedures but similar rates of adverse anesthesia events.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Abstract

Full Text

Related papers